title: Tamoxifen integromics and personalized medicine: dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment.
abstract: Recent advances in pharmacogenomics technologies allow bold steps to be taken towards personalized medicine, more accurate health planning, and personalized drug development. In this framework, systems pharmacology network-based approaches offer an appealing way for integrating multi-omics data and set the basis for defining systems-level drug response biomarkers. On the road to individualized tamoxifen treatment in estrogen receptor-positive breast cancer patients, we examine the dynamics of the attendant pharmacological response mechanisms. By means of an "integromics" network approach, we assessed the tamoxifen effect through the way the high-order organization of interactome (i.e., the modules) is perturbed. To accomplish that, first we integrated the time series transcriptome data with the human protein interaction data, and second, an efficient module-detecting algorithm was applied onto the composite graphs. Our findings show that tamoxifen induces severe modular transformations on specific areas of the interactome. Our modular biomarkers in response to tamoxifen attest to the immunomodulatory role of tamoxifen, and further reveal that it deregulates cell cycle and apoptosis pathways, while coordinating the proteasome and basal transcription factors. To the best of our knowledge, this is the first report that informs the fields of personalized medicine and clinical pharmacology about the actual dynamic interactome response to tamoxifen administration.
authors.affiliation: 1 Department of Medical Physics, School of Medicine, University of Patras , Patras, Greece .
authors.forename: Konstantina
authors.initials: K
authors.lastname: Dimitrakopoulou
authors.forename: Georgios N
authors.initials: GN
authors.lastname: Dimitrakopoulos
authors.forename: Kyriakos N
authors.initials: KN
authors.lastname: Sgarbas
authors.forename: Anastasios
authors.initials: A
authors.lastname: Bezerianos
mesh_terms: D000465:Algorithms; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017209:Apoptosis / Q000235:genetics; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D002453:Cell Cycle / Q000235:genetics; D005260:Female; D053263:Gene Regulatory Networks / Q000187:drug effects; D006801:Humans; D010597:Pharmacogenetics; D057285:Precision Medicine; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D025941:Protein Interaction Mapping; D013629:Tamoxifen / Q000627:therapeutic use*; D014157:Transcription Factors / Q000235:genetics; D059467:Transcriptome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D054316:Biomarkers, Pharmacological; D014157:Transcription Factors; D013629:Tamoxifen; D046988:Proteasome Endopeptidase Complex